Phase 1/2 Trial of ‘Off-the-shelf’ CAR T-cell Therapy for Multiple Myeloma to Open Soon
A clinical trial is soon to begin testing Precision BioSciences‘s new CAR T-cell therapy candidate, PBCAR269A, in people with relapsed or refractory multiple myeloma.